Sentences with phrase «placebo treatment groups»

Interestingly, the placebo treatment group showed a 28 % increase in serum LPS levels after 30 days of no treatment, suggesting that leaky gut may be a progressive condition that requires continuous intervention.

Not exact matches

Patients were randomised into eight treatment groups: a single dose regimen of 200, 300 or 500 mg inclisiran, or placebo; or a two dose regimen of 100, 200 or 300 mg inclisiran, or placebo, at days one and 90.

«Such a study would be feasible and ethically justifiable if one excluded certain high - risk groups so that antibiotic treatment would not be withheld from them in the placebo arm.

While 35 per cent of the patients who had not received any treatment reported an improvement, 59 per cent of the placebo group felt better.

For those in the treatment group, the number of seizures per month was cut roughly in half, on average, compared to a negligible decline in the placebo group, researchers reported this week in The New England Journal of Medicine.

TRINOVA - 2 is evaluating pegylated liposomal doxorubicin in combination with either placebo or trebananib in previously treated patients with ovarian cancer while TRINOVA - 3, also known as ENGOT - Ov2 and Gynecologic Oncology Group — 3001, is studying the use of trebananib in front - line treatment adding it to carboplatin / paclitaxel.

After nine hours, iron in the blood stream had decreased in the placebo group, whereas this decrease could be prevented by treatment with lexaptepid.

Now a group of physicians have designed the fecal treatment's first double - blind trial, in which neither patient nor researcher knows whether a placebo or a healthy microbiome is being delivered to the ailing gut.

The result: although the sex lives and sexual satisfaction of the women receiving oxytocin treatment improved significantly, the group that only received a placebo also had significantly improved scores.

Using a sample of 10 resistance - trained men in their early 20s, protein supplementation consisted of 3 treatment groups: whey protein isolate, soy protein isolate, or a maltrodextrin placebo control.

Psoriasis patients were randomly divided into two groups, with 21 patients in the placebo group and 22 patients receiving the treatment.

The treatment and placebo groups» fracture rates were 20 percent (18 women) and 16 percent (15 women), respectively, and mortality rates were 16 percent (14 women) and 13 percent (12 women), respectively.

Over six months of treatment, there was a 27.6 per cent reduction of becoming full blown MS. (The risk was 61 per cent in the placebo group and 33.4 percent in the minocycline group.)

The average spine BMD also increased more in the treatment group than placebo group at 12 months (3 percent vs. 1.1 percent) and at 24 months (4.5 percent vs. 0.7 percent).

Six weeks of treatment by the highest dose of dronabinol (10 milligrams) was associated with a lower frequency of apneas or hypopneas (overly shallow breathing) during sleep, decreased subjective sleepiness and greater overall treatment satisfaction compared to the placebo group.

Although the study began as a randomized trial that divided subjects into four treatment groups (placebo, deprenyl, α - tocopherol, and deprenyl / α - tocopherol), this was terminated early because positive effects of deprenyl were observed and all subjects then received deprenyl for approximately 18 months.

Overall, the gene therapy was well tolerated and patients in the treatment and placebo groups experienced similar rates of adverse events.

Research staff were not informed regarding which monkeys were included in the treatment vs placebo groups.

Adverse events potentially related to the study included kidney stones (16 participants in the treatment group and 10 in the placebo group) and elevated serum calcium levels (six in the treatment group and two in the placebo group).

Incidence over four years was 0.042 in the treatment group and 0.060 in the placebo group.

Contrary to the proclamations of many scientists, unreliable medical study results do not disappear with large, randomized controlled trials, in which subjects are randomly assigned to a treatment or placebo group.

Joan Lappe, Ph.D., R.N., of the Creighton University Schools of Nursing and Medicine, Omaha, and colleagues randomly assigned 2,303 healthy postmenopausal women 55 years or older (average age, 65 years) to the treatment group (n = 1,156; 2,000 IU / d of vitamin D3 and 1,500 mg / d of calcium) or to the placebo group (n = 1,147).

Furthermore, in mothers who gave birth in winter, vitamin D concentrations fell from 14 to 34 weeks gestation in the placebo group, but rose in the treatment group.

The live birth rate was 65.8 % in the treatment group, and 63.3 % in the placebo group.

The findings demonstrated that the treatment reduced both the number of migraine days per month (the active treatment group experienced a reduction of 3.6 days compared to 0.9 days in the placebo group) as well as headache pain and the consequent need for migraine abortive prescription medications.

A pooled analysis of data from two randomised trials comparing vitamin E versus placebo, and the placebo group from another trial comparing vitamin E use versus non-use, demonstrates that the efficacy of vitamin E is comparable to other treatments for NASH, including pioglitazone, metformin and obeticholic acid.

The researchers found that the addition of vitamin D3 to ciclesonide did not significantly reduce the rate of first treatment failure (a composite outcome of decline in lung function and increases in use of beta - agonists, systemic steroids, and health care utilization) compared with placebo; 28 percent and 29 percent of participants in each group, respectively, experienced at least 1 treatment failure during 28 weeks.

Compared to placebo, niraparib significantly prolonged the second progression - free survival, time to first subsequent treatment, and chemotherapy - free interval in the mutation and mutation - free groups, and in the HRD subgroup.

Only then was the group randomized into one of two groups; the treatment - as - usual (TAU) group or the open - label placebo (OLP) group.

Tony Wyss - Coray of Alkahest has had to scrap the placebo group for the safety phase of a trial of young blood plasma as a treatment for Alzheimer's because of a lack of recruits.

For the «Treatment of Severe Childhood Aggression (TOSCA) Study,» 168 children (ages 6 - 12) who had been diagnosed with ADHD and disruptive behavior disorder (DBD) and displayed severe physical aggression were randomly assigned to two groups: parent training plus stimulant plus placebo (Basic treatment) or parent training plus stimulant plus the antipsychotic drug risperidone (Augmented trTreatment of Severe Childhood Aggression (TOSCA) Study,» 168 children (ages 6 - 12) who had been diagnosed with ADHD and disruptive behavior disorder (DBD) and displayed severe physical aggression were randomly assigned to two groups: parent training plus stimulant plus placebo (Basic treatment) or parent training plus stimulant plus the antipsychotic drug risperidone (Augmented trtreatment) or parent training plus stimulant plus the antipsychotic drug risperidone (Augmented treatmenttreatment).

By the end of treatment, the odds of experiencing a heavy drinking day in the placebo group was five times more than that of the topiramate group; and the number of patients who experienced no heavy drinking days on the last four weeks of treatment in the topirmate group was more than double that of the placebo group.

The other two groups received a placebo or no treatment.

As early as 4 weeks into treatment, 21 % in the guselkumab group had a significant treatment effect on ACR20 response, compared to zero in the placebo group (p < 0.001).

Then the 198 men in the first group received daily treatment for four months with either a placebo (dummy) gel or one of four doses of testosterone gel (AndroGel, AbbVie), ranging from low to high (1.25 to 10 grams).

In the double - blind, placebo - controlled, randomized clinical trial, 16 individuals were randomly assigned to treatment (n = 8) or placebo (n = 8) groups.

After treatment, greater activation was evident on fMRI in the treatment group during performance of a memory task; no change was seen in the placebo group.

Members of the apalutamide group who continued to benefit from the drug were able to continue treatment, and members of the placebo group could begin receiving apalutamide on an open - label basis.

In many trials, some participants are randomly assigned to the «control» group and receive an inactive «placebo» treatment or a standard intervention currently in use; sometimes the control subjects are later given a chance to try the experimental treatment.

The WHI could not address the risk of death due to breast cancer because with the relatively short follow - up time, few women in the WHI have thus far died as a result of breast cancer (3 in the active treatment group and 2 in the placebo group).

Of the 69 participants with moderate to severe TBI enrolled in the study, 35 were assigned to the treatment group and 34 to the placebo group.

A total of 168 participants (85 in active treatment group; 83 receiving placebo) completed the MRI section of the trial.

If we confined the analysis to the biologically compliant subjects (n = 136), the effect of treatment was slightly greater with a reduction in atrophy rate of 31.1 % in the active treatment group (rate of atrophy: 0.73 % [0.57 — 0.88]-RRB- compared to the placebo group (1.06 % [0.90 — 1.22], P = 0.004 after multi-adjusted analysis).

The mean rate of brain atrophy per year was 0.76 % [95 % CI, 0.63 — 0.90] in the active treatment group and 1.08 % [0.94 — 1.22] in the placebo group (P = 0.001).

But comparing the placebo group versus the entire treatment group, there was not a significant effect on MACE.

A randomized trial is a type of clinical trial in which patients are assigned to groups on a random basis where they receive either the new experimental treatment or the established standard of care (or a placebo).

After six months, those who got the real Obalon treatment had lost 6.81 % of their total body weight (about 25 % of their «excess body weight,» or the amount they'd have to lose to have a BMI in the normal range), while those in the placebo group had lost only 3.59 %.

The study looked at the effect of dietary supplementation using 2,000 international units of nonprescription vitamin E daily in a large group of elderly Alzheimer's patients and compared their results over an average of around two years to similar patients who received a placebo, a pharmaceutical marketed as a «treatment» for Alzheimer's disease (memantine), or a combination of memantine along with vitamin E.

Scores for self - control and vitality were also lower in the birth control group compared to the placebo group after treatment.

Before treatment, about 35 % of both groups reported moderate to severe distress in general well - being; afterward, that number rose to 38 % in the placebo group, and 44 % in the birth control group.